‘CONDUCTING PHASE 2/3 TRIAL FOR COVID-19 VACCINE’

“Shionogi has launched its New Medium-Term Business Plan‚ STS2030’, aiming to realise our vision for 2030: Building Innovation Platforms to Shape the Future of Healthcare. We will continue to build upon our established capabilities as a drug discovery-based pharmaceutical company based on innovation and highly advanced expertise, while increasingly catalysing the formation of new healthcare platforms as the partner of choice for companies and industries with complementary capabilities and expertise in other fields. Shionogi is currently conducting a Japanese Phase 2/3 clinical trial. We will continue to consult closely with the Ministry of Health, Labor and Welfare, Pharmaceuticals and Medical Devices Agency (PMDA) and other organisations for future applications for approval. As SARS-CoV-2 continues to have a major impact on people’s lives and to represent a global threat, we will seek to contribute to re-establishing the safety and security of society by developing, delivering, and producing, in Japan, a vaccine for COVID-19.”

- DR ISAO TESHIROGI, President and Chief Executive Officer, Shionogi & Co., Japan